Megakaryocyte growth and development factor

Narhi, L.O., J.S. Philo, B. Sun, B.S. Chang, and T. Arakawa. 1999. Reversibility of heat-induced denaturation of the recombinant human megakaryocyte growth and development factor. Pharm Res 16 799-807. 

Thrombopoietin TPO megakaryocyte growth and development factor (MODE)... 

E.N. Cheung, D. Terry, and W. Sheridan. 2000. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95 2514-2522. 

Thrombopoiesis is the term used to describe the process of platelet production. The bone marrow manufactures 40,000 platelets/mL of blood each day. Proliferation and differentiation of platelet precursors are thought to be primarily influenced by cytokines such as IL-6, IL-11, leukemia inhibitory factor, and perhaps most specifically, by thrombopoietin (TPO or megakaryocyte growth and development factor see Fig. 98-6). Other hematopoietins that may act in concert, producing synergistic effects include IL-3, IL-1, GM-CSF, EPO, and Scf.34 The platelet survival time is a clinical test that can estimate the rate of platelet turnover. In healthy individuals, this time is 9.5 0.6 days.36... 

Basser RL, O Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, Cohen B, Begley CG. Development of pancytopenia with neutralizing antibodies to throm-bopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002 99 2599-2602. 

Guerra, RL, Acklin, C., Kosky, A.A., Davis, J. M., Treuheit, M.J., Brems, D.N. PEGylation prevents N-terminal degradation of megakaryocyte growth and development factor. Pharmaceutical Research, 1998 15 12 1822-1827. 

Archimbaud, E., Chnical trials of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), Haematol. Blood Transfus., 39,343,1998. 

---